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MR was performed. Subsequently, they underwent surgery. Then we
restrospectively investigated the correspondence of the complete answers
to the treatment evaluated first at the MRI (iCR) and then through the post-
operative histological examination (pCR). Subsequently, we divided the
sample of patients into three groups: luminal A/B (HER2 negative), triple
negative (TN), HER2 positive. Finally, by examining patients in whom there
was no iCR and/or pCR, we evaluated the correlation between the size of the
residual tumour mass shown on MRI and those shown by the postoperative
histological examination.
Results: MRI, in predicting a Complete Response (RC), has a sensitivity
of 55%, a specificity of 86%, a VPP of 50% and a VPN of 88%. The analysis
shows that for luminal subtypes the use of magnetic resonance imaging
leads to non-specific and heterogeneous responses with a high number of
false positivities in the face of a histological examination that shows a pCR.
The other two subgroups, on the other hand, aremore similar to each other in
terms of predictivity of imaging with a comparable percentage of false
positives and negatives. What distinguishes them, however, is the greater
specificity of resonance in the HER2+ group with 71% compared to 33% in
the triple-negative group, although among the latter imaging has shown
greater sensitivity (90% vs 64%). The correlation between the size of the
residual tumor seen through MRI and the size shown by the post-surgical
histological examination is very low (0.23) in the group of luminals.
Conclusions:MRI is sensitive but not very specific, leading in 50% to the
risk of over-treating patients and in 12% of cases to under-treating them. In
the stratification by subtype, it has also emerged that this method could be
useful and more reliable in the evaluation of the response of HER2+ and
triple-negative tumors; instead, it is considered unreliable in the evaluation of
luminal subtypes, where a histological examination is also necessary.
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Deep learning enables fully automated mitotic density assessment in
breast cancer histopathology
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Background:Mitosis counting is an important part of breast cancer grading,
yet known to suffer from observer variability. Advances in machine learning
enable fully automated analysis of digitized glass slides. The present study
evaluated automatic mitosis counting and demonstrated applicability on
triple negative breast cancers (TNBC).
Material andMethods: In entire scanned H&E slides of 90 invasive breast
tumours, a deep learning algorithm (DLA) fully automatically detected all
mitoses and determined the hotspot (area with highest mitotic density).
Subsequently, two independent observers assessed mitotic counts on glass
slides according to routine practice, and in the computer-defined hotspot.
Next, automated mitotic counting was performed in our TNBC cohort (n =
597). Multivariable Cox regression survival models were expanded with
dichotomized mitotic counts. The c-statistic was used to evaluate the
additional prognostic value of every possible cut off value.
Results: Automatic counting showed excellent concordance with visual
assessment in computer detected hotspots with intraclass correlation
coefficients (ICC) of 0.895 (95% CI 0.845–0.930) and 0.888 (95% CI
0.783–0.936) for two observers, respectively. ICC of fully automated
counting versus conventional glass slide assessment were 0.828 (95% CI
0.750–0.883 and 0.757 (95% CI 0.638–0.839), respectively (Table 1).
In the TNBC cohort, automatic mitotic counts ranged from 1 to 269 (mean
57.6) in 2 mm2 hotspots. None of the cut off values improved the models’
baseline c-statistic.
Table 1 Linear weighted kappa scores and intra class correlation coefficients






0.604 (95% CI 0.477–0.731) 0.828 (95% CI 0.750–
0.883; p < 0.001)
Observer II glass
versus CNN
0.609 (95% CI 0.484–0.734) 0.757 (95% CI 0.638–
0.839; p < 0.001)
Observer I hotspot
versus CNN
0.654 (95% CI 0.530–0.777) 0.895 (95% CI 0.845–
0.930; p < 0.001)
Observer II hotspot
versus CNN
0.794 (95% CI 0.691–0.896) 0.888 (95% CI 0.783–
0.936; p < 0.001)
Conclusion: Automatic mitosis counting is a promising complementary
aid for mitoses assessment. Our method was capable of fully automatically
locating the mitotic hotspot in tumours, and was capable of processing a
large series of TNBC, showing that mitotic count was not prognostic for
TNBC even when attempting alternative cut off points.
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Prone, stereotactic, vacuum-assisted breast biopsy
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Budapest, Hungary; 2Affidea Hungary Váci Greens, Radiology, Budapest,
Hungary
Background:Stereotactic VAB is the gold standard in the biopsy guidance of
nonpalpable breast lesions which cannot be detected on ultrasound. The aim
of this study is to learn about prone, stereotactic, vacuum-assisted core
biopsy (PS VAB) systems through our experience:
• Basic concept, types, future advancements
• Utilization
• Advantages and disadvantages
• BI-RADS lesions
Material and Methods: Between 2010–2019, 1600 cases were docu-
mented, 90% due to microcalcifications. System: guidance-table combo and
biopsy device. The patient lies prone, her breast is compressed. After
targeting, sampling/excision is done under local anaesthesia with 7–9 G
needles from multiple angles. Markers may be used at the end of the
procedure to mark the site of the biopsied lesion.
Results: 53.4% B2, 10.8% B3 and 35.2% B4-5 lesions in concordance to
the literature. Enough sample for the extremely precise diagnosis leads to 55%
less surgeries and 75% less two-step surgeries. Digital breast tomosynthesis
might further facilitate targeting, sampling and might broaden the scope of
lesion identification. This is currently under investigation.
PS-VAB in particular, compared to seated variants, offers more comfort to
the patient, meanwhile eliminating collapses and promoting effortless,
precise targeting shortening diagnostic workup. No specific preparation is
needed from the patient, even anticoagulation-therapies are not necessary to
be suspended.
Conclusions:VAB is the gold standard in lesions that are not palpable and
cannot be detected on ultrasound (mostly microcalcifications).
Provides enough sample for the extremely precise preoperative
diagnosis.
• Can be therapeutic (papillomas, radial scars, smaller fibroadenomas)
• Site markers can be used, when necessary (might migrate)
• Surgeries are reduced by 55%, two-stage surgeries by 75%
• Prone systems are more comfortable and eliminate collapses, while
promoting precise targeting
• Few prone systems are operating in Hungary (only one with tomosynth-
esis), it is expensive and underfinanced (2400 cases annually, 200
financed)
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The relative eosinophil count in breast cancer as an emerging
prognostic biomarker
C.E. Onesti1, C. Josse2, B. Beaumecker1, D. Boulet2, J. Thiry2, V. Bours2,
G. Jerusalem1. 1CHU Liège, Medical Oncology, Liège, Belgium; 2GIGA
Research Center, Laboratory of Human Genetics, Liège, Belgium
Background:Cancer outcome appears to be affected by circulating immune
cells in several tumor types. The role of peripheral eosinophils was widely
studied in melanoma, while less data are available for breast cancer (BC) so
far. In a previous study, we showed an association between baseline relative
eosinophil count (REC), pathological complete response and survival rate in
triple negative and hormone receptor negative/HER2 positive breast cancer.
In this retrospective study we analyzed the role of REC in all breast cancer
subtypes at time of diagnosis and during follow-up.
Material and Methods: Stage I-III BC patients (pts) treated between 1999
and 2018 were included in the study. REC and relative lymphocyte count
(RLC) at seven different timepoints were collected. The pts were divided into
two groups according toREC, using 1.5%as threshold, and according toRLC,
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using 17.5% as threshold. The co-primary endpoints were the BC specific
survival (BCSS) and the time to treatment failure (TTF) according to REC. The
secondary endpoints were: BCSS and TTF according to RLC, the association
between REC and RLC with relapse; the variation of REC during follow-up
and at relapse. Statistical analysis was done with SPSS v25 software.
Results: Overall 930 early BC pts were included in the study. The median
age of the whole cohort was 61 years (25–97). The pts were well balanced
according to the TNM stage in the group REC-low (393 pts) and in the group
REC-high (597 pts): 30.5% and 32.9% stage I; 45.3% and 45.1% stage II;
22.6% and 21.4% stage III respectively; 1.4% unknown. After a median
follow-up of 91 months (range 1–245) we observed a benefit in TTF (HR
0.610–95% CI 0.458–0.812, p 0.001) and BCSS (HR 0.632–95%CI 0.433–
0.923, p 0.018) in REC-high vs REC-low group. A survival benefit was
observed also in the RLC-high vs RLC-low group (TTF: HR 0.421–95%
CI 0.262–0.677, p 0.001; BCSS: HR 0.350–95% CI 0.2–0.614, p 0.001).
A lower rate of relapse was observed in the REC-high vs REC-low group
(17.1% vs 24.7%, p 0.005) and in the RLC-high vsRLC-low group (19.4% vs
35.8%, p 0.004). We observed a lower median REC at baseline before
surgery (1.8% and 1.4% in pts without and with relapse respectively),
compared to the median value after surgery (2.7% and 2.5% respectively),
that remain stable until 10 years of postsurgical follow up in cancer free pts.
A decrease in median REC was detected at time of relapse (1.5%). All the
differences observed in the groups of pts with and without tumor recurrence
were statistically significant (p < 0.0001), suggesting a role of the presence of
cancer in the modulation of eosinophil count.
Conclusions: REC could be a new promising, affordable and accessible
predictive and prognostic biomarker in all BC subtypes. Mechanistic studies,
ongoing in our laboratory, are needed to understand eosinophils’ physio-
pathological role.
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Diagnostic work-up in women suspect for breast cancer in the
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Introduction: The goal of this study is to outline the hospital-based work-up
during the diagnostic care pathway of women suspect for breast cancer in the
Netherlands and to identify factors which influence this diagnostic work-up.
Method: Two cohorts have been analyzed: the “benign” cohort (n =
30,334 women suspect for breast cancer from ten hospitals) and the
“malignant” cohort (n = 2,236 breast cancer patients from five hospitals).
Hospital-based financial data in combination with tumor data (malignant
cohort) from the Netherlands Cancer Registry was used. Patterns within the
diagnostic care pathway were analyzed for both the benign and malignant
cohort. For the women with finally diagnosis of breast cancer factors
influencing the number of diagnostic care activities number of days until
diagnosis of breast cancer were identified in the malignant cohort using
multivariable Poisson regression models. To determine the factors influen-
cing the number of days until diagnosis of breast cancer in the malignant
cohort multivariable Cox regression models were used.
Results: Patients finally diagnosed with malignant disease had their
diagnosis less often in one day (62% versus 67%) and on average had an
equal number of average hospital visits (1.6) and a higher average number
diagnostic care activities (4.7 versus 2.6) compared to patients with benign
breast lesions. Of patients with malignant disease receiving triple-diagnos-
tics, 87% were diagnosed during their first hospital visit. Factors influencing
the number of diagnostic care activities were: individual hospital (IRR ranged
between 0.89, 95%CI 0.84–0.95 to 1.22, 95%CI 1.16–1.29), higher age at
diagnosis (continuous; IRR 0.998, 95%CI 0.996–0.999), palpable tumor (yes
vs no; IRR 0.96, 95%CI 0.93–1.00), metastasis suspect lymph nodes (cN2
vs cN0; IRR 1.3, 95%CI 1.0–1.7; cN3 vs cN0; IRR 1.16, 95%CI 1.0–1.3),
localization (central vs inner quadrant; IRR 0.93, 95%CI 0.88–0.99) and
histology (other vs ductal; IRR 0.92, 95%CI 0.86–0.99). Factors influencing
the number of days until (malignant) diagnosis were: hospital (IRR ranged
between 1.12, 95%CI 1.09–1.35 and 1.3, 95%CI 1.19–1.42), higher BIRADS
score (2/3 versus 0/1/unknown IRR 0.79 95%CI 0.66–0.95), detected by
screening (yes vs no IRR 1.13, 95%CI 1.04–1.22), metastasis (cM1 vs cM0;
IRR 0.70, 95%CI 0.54–0.91), and cT stage (cT2 vs cT1 IRR 1.16, 95%CI
1.05–1.28).
Conclusion: The diagnostic work-up of patients finally diagnosed with
malignant disease demanded more time and diagnostic care activities than
for those with benign lesions and was influenced by hospital, tumor and
patient characteristics. This knowledge can improve the diagnostic care
pathway and decrease variation.
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Is sentinel lymph node biopsy necessary in the setting of
microinvasive DCIS?
K. Desai1, R. Pham1, J. Shin1, K. Horn1, A. Harbhajanka1, L. Sieck1.
1University Hospitals, Cleveland, Ohio, Breast Imaging, Cleveland, USA
Background: Breast cancer treatment guidelines recommend the surgeon
perform a sentinel lymph node biopsy (SLNB) for patients with ductal
carcinoma in situ (DCIS) who have a high risk of invasive cancer or for whom
a mastectomy is planned.
Material and Methods: Our retrospective review evaluates patients
diagnosed with DCIS or DCIS with microinvasion who were clinically node
negative and had SLNB from 2005–2017. A diagnosis of DCIS does not
routinely merit SLNB. However, a diagnosis of DCIS with microinvasion is
considered a more aggressive form of DCIS and surgeons at our institution
routinely perform SLNB in this setting, even though the patients are clinically
node negative. SLNB is performed due to the concern for possible
understaging of DCIS at the time of core needle biopsy in order to exclude
the possibility of occult axillary metastatic disease. Our hypothesis is that
metastatic disease is not routinely diagnosed in patients with DCIS with
microinvasion. SLNB is not without morbidity; the literature quotes about a
5% chance of postoperative lymphedema (McLaughlin et al. J Clin Oncol.
2008 Nov 10;26(32):5213–9).
Results:At this time in ourongoingdatacollection,wehave lookedat a total
of 75 patients who had DCIS with microinvasion and 56 patients who had
DCIS only. Sixty four (85.3%) of patients with DCIS with microinvasion had
SLNB. Sixteen patients (28.6%)with DCIS only had SLNB, whichwe surmise
was due to surgeon preference. The SLNB results for the 64 patients with
DCIS with microinvasion are as follows: 89.1% were pN0, 3.1% were pN0i,
3.1% were pN1mi, and 4.7% were pN1a. Both pN1mi and pN1a are
considered clinically significant metastatic disease to the axillary lymph
nodes. Of the 75 patients who had DCIS with microinvasion, 92.2% of the
patients did not haveclinicallysignificant axillarymetastatic disease.Of the16
patients who hadDCIS only and SLNB, none had axillarymetastatic disease.
Conclusions: Given the low rate of significant metastatic disease to the
axillary lymph nodes, even in the setting of DCIS with microinvasion, our
preliminary results support our hypothesis that SLNB could be omitted in
these patients. These results correlate with Roozendaal’s study of 910
patients in the Netherlands (Breast Cancer Research Treatment 2016
156:517–525); Roozendaal’s study found that 79.5% of the patients with
DCISwithmicroinvasion were pN0, 4.9%were pN0i+, 6.6%were pN1mi, and
9% were pN1. Clinical relevance: Our results support the omission of SLNB
for patients with DCIS with microinvasion; this will reduce the morbidity of
postoperative side effects such as lymphedema in this patient population.
Additionally, even though there were few patients with DCIS who underwent
SLNB, this study reinforces the fact that these patients should not have
SLNB.
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Reconsidering the management of palpable DCIS: a single institution
audit
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S. Murali1, V. Vanmali3, B. Bandare3, S. Gupta4, R. Badwe1. 1Tata Memorial
Centre, Surgical oncology, Mumbai, India; 2Tata Memorial Centre,
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Background: Ductal carcinoma in situ (DCIS) identified by screening
mammography accounts for 20% of breast cancer diagnoses, and
microinvasion (DCIS-M) is found in 5%–10%. There are no defined treatment
guidelines for palpable DCIS or DCIS-M. The role of screening
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